Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Therapy: Clinical

A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jacquin Jones, Theresa Ferrara, Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlom and James L. Gulley
Mahsa Mohebtash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kwong-Yok Tsang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravi A. Madan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ngar-Yee Huen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane J. Poole
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Jochems
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacquin Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa Ferrara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher R. Heery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip M. Arlen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seth M. Steinberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Pazdur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myrna Rauckhorst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth C. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William L. Dahut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Schlom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James L. Gulley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-11-0649
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: PANVAC is a recombinant poxviral vaccine that contains transgenes for MUC-1, CEA, and 3 T-cell costimulatory molecules. This study was conducted to obtain preliminary evidence of clinical response in metastatic breast and ovarian cancer patients.

Experimental design: Twenty-six patients were enrolled and given monthly vaccinations. Clinical and immune outcomes were evaluated.

Results: These patients were heavily pretreated, with 21 of 26 patients having 3 or more prior chemotherapy regimens. Side effects were largely limited to mild injection-site reactions. For the 12 breast cancer patients enrolled, median time to progression was 2.5 months (1–37+) and median overall survival was 13.7 months. Four patients had stable disease. One patient had a complete response by RECIST and remained on study for 37 months or more, with a significant drop in serum interleukin (IL)-6 and IL-8 by day 71. Another patient with metastatic disease confined to the mediastinum had a 17% reduction in mediastinal mass and was on study for 10 months. Patients with stable or responding disease had fewer prior therapies and lower tumor marker levels than patients with no evidence of response. For the ovarian cancer patients (n = 14), the median time to progression was 2 months (1–6) and median overall survival was 15.0 months. Updated data are presented here for one patient treated with this vaccine in a previous trial, with a time to progression of 38 months.

Conclusions: Some patients who had limited tumor burden with minimal prior chemotherapy seemed to benefit from the vaccine. Further studies to confirm these results are warranted. Clin Cancer Res; 17(22); 1–10. ©2011 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

  • Received March 14, 2011.
  • Revision received August 22, 2011.
  • Accepted September 11, 2011.
  • ©2011 American Association for Cancer Research.
Next
Back to top

Published OnlineFirst November 8, 2011
doi: 10.1158/1078-0432.CCR-11-0649

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jacquin Jones, Theresa Ferrara, Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlom and James L. Gulley
Clin Cancer Res November 8 2011 DOI: 10.1158/1078-0432.CCR-11-0649

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jacquin Jones, Theresa Ferrara, Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlom and James L. Gulley
Clin Cancer Res November 8 2011 DOI: 10.1158/1078-0432.CCR-11-0649
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Andecaliximab alone and combined in gastric/GEJ cancer
  • Tumor growth inhibition-OS model for atezolizumab in NSCLC
  • Impact of baseline tumor size on outcomes in melanoma
Show more Cancer Therapy: Clinical
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement